EP
JSPR icon

Essential Partners’s Jasper Therapeutics JSPR Stock Holding History

Essential Partners’s Portfolio JSPR Stock Details JSPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-72
Closed -$400 – 2735
2025
Q2 		$400 Buy
+72
New +$354 ﹤0.01% 1761

Other funds holding JSPR

VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $191M AUM 102.42% 1-Year Est. Return

Essential Partners's JSPR Position: Q3 2025 in Review

Essential Partners sold out of Jasper Therapeutics (JSPR) in Q3 2025, closing a stake of 72 shares — an estimated $400 sold.

Essential Partners first reported a position in JSPR in Q2 2025 and held it in 1 quarter. The position peaked at $400 in Q2 2025. 60 funds tracked by Wall St. Rank hold JSPR as of Q3 2025.

  • Essential Partners reported no remaining Jasper Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Essential Partners sold 72 Jasper Therapeutics shares in Q3 2025, an estimated $400.
  • Essential Partners first reported a position in Jasper Therapeutics in Q2 2025 and held it in 1 quarter.
  • Essential Partners's Jasper Therapeutics position peaked at $400 in Q2 2025.
  • 60 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q3 2025.

Based on Essential Partners's 13F filing for Q3 2025, filed 21 May 2026.